Experimental IV drug targets deadly fevers in military personnel
NCT ID NCT02483260
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial investigates whether intravenous ribavirin can help treat people with Crimean-Congo hemorrhagic fever or Lassa fever, two severe viral infections. The study enrolls up to 30 military-affiliated adults who have a probable or suspected case. Participants receive a specific dosing regimen of ribavirin over 10 days, and researchers monitor for side effects and outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ribavirin (intravenous)
- What this could lead to
- If effective, ribavirin could provide a treatment option for these rare but severe viral fevers, potentially reducing complications.
- What could go wrong
- This is a small, early-stage protocol with only 30 participants, so results may not apply broadly. Ribavirin can cause side effects like anemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRIMEAN CONGO HEMORRHAGIC FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Landstuhl Regional Medical Center
Landstuhl, APO AE, 09180, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.